PREVALENCE OF MAJOR DEPRESSION IN PATIENTS WITH BREAST CANCER

Autores

  • Sionara Melo Figueiredo de Carvalho Laboratório de Delineamento de Estudos e Escrita Científica da Faculdade de Medicina do ABC, Santo André-SP, Brazil./ Universidade Federal do Cariri, Faculdade de Medicina, Barbalha-CE, Brazil.
  • Italla Maria Pinheiro Bezerra Laboratório de Delineamento de Estudos e Escrita Científica da Faculdade de Medicina do ABC, Santo André-SP, Brazil.
  • Thiago Holanda Freitas Universidade de Fortaleza, Fortaleza-CE, Brazil.
  • Ricardo César da Silva Rodrigues Laboratório de Delineamento de Estudos e Escrita Científica da Faculdade de Medicina do ABC, Santo André-SP, Brazil.
  • Idelfonso Oliveira Chaves de Carvalho Laboratório de Delineamento de Estudos e Escrita Científica da Faculdade de Medicina do ABC, Santo André-SP, Brazil.
  • Aline Quental Brasil Universidade Federal do Cariri, Faculdade de Medicina, Barbalha-CE, Brazil.
  • Francisco Telésforo Celestino Júnior Universidade Federal do Cariri, Faculdade de Medicina, Barbalha-CE, Brazil.
  • Lucyo Flávio Bezerra Diniz Laboratório de Delineamento de Estudos e Escrita Científica da Faculdade de Medicina do ABC, Santo André-SP, Brazil.
  • Alexandra Paz-Cox Laboratório de Delineamento de Estudos e Escrita Científica da Faculdade de Medicina do ABC, Santo André-SP, Brazil.
  • Luiz Carlos de Abreu Laboratório de Delineamento de Estudos e Escrita Científica da Faculdade de Medicina do ABC, Santo André-SP, Brazil.

DOI:

https://doi.org/10.7322/jhgd.96770

Palavras-chave:

breast cancer, breast neoplasms, prevalence, cross-sectional studies, major depression, mood disorders.

Resumo

Introduction: breast cancer is one of the main causes of death among women in Brazil and worldwide. The diagnosis of breast neoplasms usually represents an emotional burden, and it may lead to adjustment reactions and even be the trigger for affective disorders (mainly depression), anxiety or psychosis. The Beck Depression Inventory (BDI) is one of the most used mechanisms for the evaluation of depression in research and in clinics. Depression prevalence in patients with cancer varies from 3% to 55% among different studies. Methodological variation, different instruments to assess depression and different cut-off points for diagnosis contribute to the huge discrepancy in current findings. In general, the more specifically depression is defined and evaluated, the lower the rates of prevalence are reported. Many articles fail to demonstrate a statistical significance in the relationship between depression and cancer-specific factors. This suggests that risk factors for depression in those patients are more related to the patient as contextual variables and premorbid factors of personality – and not to the cancer or its treatment. Objective: to determine the prevalence of major depression in women with breast cancer. Methods: a cross-sectional study was conducted in women with breast cancer. The sample consisted of 51 patients who answered the Beck Depression Inventory (BDI). The presence of depression was considered in cases where the scores were above 20. A questionnaire with additional data about the patients such as age, marital status, ethnicity, education, family income, family history of depression and breast cancer, and cancer-related variables including staging, months since diagnosis, treatment modality, type of surgery, alopecia occurring were used. Descriptive analysis and test of association (chi-square) were conducted. Results: the prevalence of major depression was 5.9%, similar to that observed in community samples. Subsyndromal depressive symptoms had a score of 21.6% (BDI scores from 16 to 20). Chi-square test was conducted and showed no statistically significant relationship between the classification of BDI and the variables tested (characteristics related to patient and cancer-specific). This indicates that the isolated context of the variables does not influence the event of depression. Conclusion: the prevalence of major depression in women with breast neoplasms was 5.9%.

Referências

World Health Organization [internet homepage]. Genebra: The Organization; c2008. [cited 2014 May 07] Available from: http://www.who.int/en.

Instituto Nacional do Câncer [internet homepage]. Estimativa para o biênio 2014/2015: incidência de câncer no Brasil. Rio de Janeiro: INCA- Ministério da Saúde, c1996- 2012. [cited 2014 May 07] Available from: http://www.inca.gov.br.

Carvalho SMF, Rolim Neto ML, Abreu LC, Celestino Junior FT. A panorama of cancer in Brazil. Neurobiologia. 2012; 75(1-2): 206-8.

Hamaker ME, Jonker JM, Rooij SE, Gvos A, Smorenburg CH, Munster BC. Frailty screening methods for predicting outcome of acomprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012; 13(10): e437-44. doi: 10.1016/S1470-2045(12)70259-0.

Cangussu RO, Soares TBC, Barra AA, Nicolato R. Sintomas depressivos no câncer de mama: Inventário de Depressão de Beck – Short Form. J Bras Psiquiatr. 2010;59(2): 106-110.

Cantinelli FS, Camacho RS, Smaletz O, Gonsales BK, Braguittoni E, Rennó Jr J. A oncopsiquiatria no câncer de mama – considerações a respeito de questões do feminino. Rev Psiquiatr Clin. 2006; 33(3): 124-133.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (DSM IV-TR) 4ª ed. Washington, DC: American Psychiatric Association; 2000.

Mitchell AJ, Cham M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorderin oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011; 12(2): 160-74. doi: 10.1016/S1470-2045 (11)70002-X.

Spiegel D. Cancer and depression. B J Psych. 1996; 168(30): 109-16.

Somerset W, Stout SC, Miller AH, Musselman D. Breast cancer and depression. Oncology. 2004; 18(8):1021-1034.

Fallowfield L, Hall A, Maguire GP, Baum M. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. BMJ. 1990; 301(6752):575-580.

Golden-Kreutz DM, Andersen BL. Depressive symptoms after breast cancer surgery: relationships with global, cancer-related, and life event stress. Psychooncology. 2004; 13(3): 211-20. Doi: 10.1002/pon.736.

Pasquini M, Biondi M. Depression in cancer patients: a critical review. Bio Med Central. 2007; 3 (2):1-9. doi: 10.1186/1745-0179-3-2.

Popoola AO, Adewuya AO. Prevalence and correlates of depressive disorders in out patients with breast cancer in Lagos, Nigeria. Psychooncology. 2012; 21(6): 675-9. Doi: 10.1002/pon.1968

Ell K, Sanchez K, Vourlekis B, Lee PJ, Dwight-Johnson M, Lagomasino I, et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynocologic cancer. J Clin Oncol. 2005; 23(13): 3052-60. Doi: 10.1200/JCO.2005.08.041.

Bardwell WA, Natarajan L, Dimsdale JE, Rock CL, Mortimer JE, Hollenbach K, et al. Objective cancer-related variables are not associated with depressive symptoms in women treated for early-stage breast cancer. J Clin Oncol. 2006; 24(16):2420-7. Doi: 10.1200/JCO.2005.02.0081

Wong-Kim EC, Bloom JR. Depression experience by young women newly diagnosed with breast cancer. Psychooncology. 2005; 14(7): 564-73. Doi: 10.1002/pon.873

Miller SL, Jone LE, Carney CP. Psychiatric sequelae following breast cancer chemotherapy: a pilot study using claims data. Psychosomatics. 2005; 46(6): 571-22. Doi: 10.1176/appi.psy.46.6.517.

Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002; 94(1): 39-49. Page 73.

Burguess C, Cornelius V, Love S, Burguess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observation a cohort study. BMJ. 2005; 330(7493):702.

Doi: 10.1136/bmj.38343.670868.D3.

Aukst-Margetic B, Jakovljevic M, Margetic B, Biscan M, Samija M. Religiosity, depression and pain in patients with breast cancer. Gen Hosp Psychiatry. 2005; 27(4): 250-55. Doi; 10.1016/j.genhosppsych.2005.04.004

Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004; (32): 57-71. Doi: 10.1093/jncimonographs/lgh014

Esposito E, Wang JL, Adair CE, Williams JV, Dobson K, Schopflocher D, et al. Frequency and adequacy of depression treatment in a Canadian population sample. Can J Psychiatry. 2007; 52(12): 780-9.

Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systemactic review of the literature. Can J Psychiatry. 2004; 49(2): 124-38.

Dunn G, Sham P, Hand D. Statistics and the nature depression. Psychol Med. 1993; 23(4):871-89.

Gorenstein C, Andrade L. Validation of Portuguese version of the Beck depression inventory and the state-trait anxiety inventory in Brazilian subjects. Braz J Med and Biol Res. 1996; 29(4): 453-57.

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh G. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4: 53-63.

Gorenstein C, Andrade L. Inventário de Beck: propriedades psicométricas da versão em Português. Rev Psiq Clin. 1998; 25(5):245-50.

Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck depression inventoty: twenty-five years of evaluation. Clin Psycol Rev. 1988; 8(1): 77-100. Doi: 10.1016/0272-7358(88)90050-5

Kendall PC, Hollon SD, Beck AT, Hammen CI, Ingram RE. Issues and recommendations regarding use of the beck depression inventory. Cognitive Ther Research. 1987; 11(3):289-99.

Schlegel RJ, Manning MA, Molix LA, Talley AE, Bettencourt BA. Predictors of depressive symptoms among breast cancer patients during the first year post diagnosis. Psychol Health. 2012; 27(3): 277-93. doi: 10.1080/088

2011.559232.

Aapro M, Cull A. Depression in breast cancer patients: the need for treatment. Ann Oncol. 1999; 10: 627-36.

Leedham B, Ganz PA. Psychosocial concerns and quality of line in breast cancer survivors. Cancer Invest. 1999; 17(5): 342-48.

Schag CA, Ganz PA, Polinsky ML, Fred C, Hirji K, Petersen L. Characteristics of women at risk for psychosocial distress in the year after breastcancer. J Clin Oncol. 1993; 11(4): 783-93.

Atrash HK, Carpentier R. The evolving role of public health in the delivery of health care. Rev Bras Crescimento Desenvolv Hum. 2012; 22(3): 396-99.

Downloads

Publicado

2015-04-07

Edição

v. 25 n. 1 (2015)

Seção

Pesquisa Original

Licença

CODE OF CONDUCT FOR JOURNAL  PUBLISHERS

 

Publishers who are Committee on Publication Ethics members and who support COPE membership for journal editors should:

 

Publishers should:

 

  • Define the relationship between publisher, editor and other parties in a contract
  • Respect privacy (for example, for research participants, for authors, for peer reviewers)
  • Protect intellectual property and copyright
  • Foster editorial independence

 

Publishers should work with journal editors to:

 

  • Set journal policies appropriately and aim to meet those policies, particularly with respect to:

–         Editorial  independence

–         Research ethics, including confidentiality, consent, and the special requirements for human and animal research

–         Authorship

–         Transparency and integrity (for example, conflicts of interest, research funding, reporting standards

–         Peer review and the role of the editorial team beyond that of the journal editor

–         Appeals and complaints

  • Communicate journal policies (for example, to authors, readers, peer reviewers)
  • Review journal policies periodically, particularly with respect to new recommendations from the COPE
  • Code of Conduct for Editors and the COPE Best Practice Guidelines
  • Maintain the integrity of the academic record
  • Assist the parties (for example, institutions, grant funders, governing bodies) responsible for the investigation of suspected research and publication misconduct and, where possible, facilitate in the resolution of these cases
  • Publish corrections, clarifications, and retractions
  • Publish content on a timely basis